|
1
|
Arnold M, Ferlay J, van Berge Henegouwen
MI and Soerjomataram I: Global burden of oesophageal and gastric
cancer by histology and subsite in 2018. Gut. 69:1564–1571. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
GBD 2017 Oesophageal Cancer Collaborators:
The global, regional, and national burden of oesophageal cancer and
its attributable risk factors in 195 countries and territories,
1990-2017: A systematic analysis for the global burden of disease
study 2017. Lancet Gastroenterol Hepatol. 5:582–597. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Laarhoven HW: Is chemotherapy for
advanced or metastatic oesophageal squamous cell carcinoma no
longer needed? Lancet Oncol. 21:743–745. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Y, Xie C, Yang H, Ho JWK, Wen J, Han L,
Lam KO, Wong IYH, Law SYK, Chiu KWH, et al: Computed
tomography-based deep-learning prediction of neoadjuvant
chemoradiotherapy treatment response in esophageal squamous cell
carcinoma. Radiother Oncol. 154:6–13. 2021. View Article : Google Scholar
|
|
5
|
Leng XF, Daiko H, Han YT and Mao YS:
Optimal preoperative neoadjuvant therapy for resectable locally
advanced esophageal squamous cell carcinoma. Ann N Y Acad Sci.
1482:213–224. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsu PK, Yeh YC, Chien LI, Huang CS and Hsu
HS: Clinicopathological significance of pathologic complete lymph
node regression after neoadjuvant chemoradiotherapy in esophageal
squamous cell carcinoma. Ann Surg Oncol. 28:2048–2058. 2021.
View Article : Google Scholar
|
|
7
|
Chen S, Yang M, Wang C, Ouyang Y, Chen X,
Bai J, Hu Y, Song M, Zhang S and Zhang Q: Forkhead box D1 promotes
EMT and chemoresistance by upregulating lncRNA CYTOR in oral
squamous cell carcinoma. Cancer Lett. 503:43–53. 2021. View Article : Google Scholar
|
|
8
|
Chang WM, Chang YC, Yang YC, Lin SK, Chang
PM and Hsiao M: AKR1C1 controls cisplatin-resistance in head and
neck squamous cell carcinoma through cross-talk with the STAT1/3
signaling pathway. J Exp Clin Cancer Res. 38:2452019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oshimori N, Oristian D and Fuchs E: TGF-β
promotes heterogeneity and drug resistance in squamous cell
carcinoma. Cell. 160:963–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mohapatra P, Shriwas O, Mohanty S, Ghosh
A, Smita S, Kaushik SR, Arya R, Rath R, Das Majumdar SK, Muduly DK,
et al: CMTM6 drives cisplatin resistance by regulating Wnt
signaling through the ENO-1/AKT/GSK3β axis. JCI Insight.
6:e1436432021.
|
|
11
|
Liu Z, Gu S, Lu T, Wu K, Li L, Dong C and
Zhou Y: IFI6 depletion inhibits esophageal squamous cell carcinoma
progression through reactive oxygen species accumulation via
mitochondrial dysfunction and endoplasmic reticulum stress. J Exp
Clin Cancer Res. 39:1442020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L,
Yu Y, Liu S, Li S, Li Z and Sun L: Tolerance to endoplasmic
reticulum stress mediates cisplatin resistance in human ovarian
cancer cells by maintaining endoplasmic reticulum and mitochondrial
homeostasis. Oncol Rep. 34:3051–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren T, Zhang H, Wang J, Zhu J, Jin M, Wu
Y, Guo X, Ji L, Huang Q, Zhang H, et al: MCU-dependent
mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2
pathway to promote ROS production and metastasis of HCC cells.
Oncogene. 36:5897–5909. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui C, Yang J, Fu L, Wang M and Wang X:
Progress in understanding mitochondrial calcium uniporter
complex-mediated calcium signalling: A potential target for cancer
treatment. Br J Pharmacol. 176:1190–1205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vultur A, Gibhardt CS, Stanisz H and
Bogeski I: The role of the mitochondrial calcium uniporter (MCU)
complex in cancer. Pflugers Arch. 470:1149–1163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Jin M, Wang Y, Zhu J, Tan R, Zhao
J, Ji X, Jin C, Jia Y, Ren T and Xing J: MCU-induced mitochondrial
calcium uptake promotes mitochondrial biogenesis and colorectal
cancer growth. Signal Transduct Target Ther. 5:592020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tosatto A, Sommaggio R, Kummerow C,
Bentham RB, Blacker TS, Berecz T, Duchen MR, Rosato A, Bogeski I,
Szabadkai G, et al: The mitochondrial calcium uniporter regulates
breast cancer progression via HIF-1α. EMBO Mol Med. 8:569–585.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stoica SI, Onose G, Pitica IM, Neagu AI,
Ion G, Matei L, Dragu LD, Radu LE, Chivu-Economescu M, Necula LG,
et al: Molecular aspects of hypoxic stress effects in Chronic
ethanol exposure of neuronal cells. Curr Issues Mol Biol.
45:1655–1680. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue W, Shen Z, Li L, Zheng Y, Yan D, Kan Q
and Zhao J: Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate
NSD2-induced cisplatin resistance in esophageal squamous cell
carcinoma. Mol Ther Nucleic Acids. 23:592–602. 2020. View Article : Google Scholar
|
|
20
|
Cui W, Fang T, Duan Z, Xiang D, Wang Y,
Zhang M, Zhai F, Cui X and Yang L: Dihydroartemisinin sensitizes
esophageal squamous cell carcinoma to cisplatin by inhibiting sonic
hedgehog signaling. Front Cell Dev Biol. 8:5967882020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Ji H, Zhu Q, Yu X, Du J and Jiang
Z: Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of
esophageal squamous cell carcinoma in vitro and in vivo. Oncol
Lett. 17:5012–5022. 2019.PubMed/NCBI
|
|
22
|
Barra GB, Santa Rita TH, Almeida ALSC,
Jácomo RH and Nery LFA: Serum has higher proportion of Janus kinase
2 V617F mutation compared to paired EDTA-whole blood sample: A
model for somatic mutation quantification using qPCR and the 2
method. Diagnostics (Basel). 10:1532020. View Article : Google Scholar
|
|
23
|
Sugimura K, Yamasaki M, Yasuda T, Yano M,
Hirao M, Fujitani K, Kimura Y, Miyata H, Motoori M, Takeno A, et
al: Long-term results of a randomized controlled trial comparing
neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel,
cisplatin, and 5-fluorouracil followed by surgery for esophageal
cancer (OGSG1003). Ann Gastroenterol Surg. 5:75–82. 2020.
View Article : Google Scholar
|
|
24
|
Liu H, Zhang J, Luo X, Zeng M and Xu L,
Zhang Q, Liu H, Guo J and Xu L: Overexpression of the long
noncoding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal
squamous cell carcinoma through the miR-195/Akt/mTOR axis. Oncol
Res. 28:65–73. 2020. View Article : Google Scholar
|
|
25
|
Suo D, Wang L, Zeng T, Zhang H, Li L, Liu
J, Yun J, Guan XY and Li Y: NRIP3 upregulation confers resistance
to chemoradiotherapy in ESCC via RTF2 removal by accelerating
ubiquitination and degradation of RTF2. Oncogenesis. 9:752020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou T, Fu H, Dong B, Dai L, Yang Y, Yan W
and Shen L: HOXB7 mediates cisplatin resistance in esophageal
squamous cell carcinoma through involvement of DNA damage repair.
Thorac Cancer. 11:3071–3085. 2020. View Article : Google Scholar :
|
|
27
|
Ben-David U, Siranosian B, Ha G, Tang H,
Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R, et
al: Genetic and transcriptional evolution alters cancer cell line
drug response. Nature. 560:325–330. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
PCAWG Transcriptome Core Group; Calabrese
C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann
KV, Liu F, Shiraishi Y, et al: Genomic basis for RNA alterations in
cancer. Nature. 578:129–136. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Song X, Cheng G, Zhang J, Dong L,
Bai J, Luo D, Xiong Y, Li S, Liu F, et al: The regulatory mechanism
and biological significance of mitochondrial calcium uniporter in
the migration, invasion, angiogenesis and growth of gastric cancer.
Onco Targets Ther. 13:11781–11794. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu P, Zhang X, Ni W, Fan H, Xu J, Chen Y,
Zhu J, Gu X, Yang L, Ni R, et al: Upregulated HOXC8 expression is
associated with poor prognosis and oxaliplatin resistance in
hepatocellular carcinoma. Dig Dis Sci. 60:3351–3363. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kamer KJ, Jiang W, Kaushik VK, Mootha VK
and Grabarek Z: Crystal structure of MICU2 and comparison with
MICU1 reveal insights into the uniporter gating mechanism. Proc
Natl Acad Sci USA. 116:3546–3555. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patron M, Checchetto V, Raffaello A,
Teardo E, Vecellio Reane D, Mantoan M, Granatiero V, Szabò I, De
Stefani D and Rizzuto R: MICU1 and MICU2 finely tune the
mitochondrial Ca2+ uniporter by exerting opposite effects on MCU
activity. Mol Cell. 53:726–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang C, Jacewicz A, Delgado BD, Baradaran
R and Long SB: Structures reveal gatekeeping of the mitochondrial
Ca2+ uniporter by MICU1-MICU2. Elife. 9:e599912020.
View Article : Google Scholar
|
|
34
|
Lee J, Kim B, Jung HA, La Choi Y and Sun
JM: Nivolumab for esophageal squamous cell carcinoma and the
predictive role of PD-L1 or CD8 expression in its therapeutic
effect. Cancer Immunol Immunother. 70:1203–1211. 2021. View Article : Google Scholar
|
|
35
|
McBride S, Sherman E, Tsai CJ, Baxi S,
Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, et al:
Randomized phase II trial of nivolumab with stereotactic body
radiotherapy versus nivolumab alone in metastatic head and neck
squamous cell carcinoma. J Clin Oncol. 39:30–37. 2021. View Article : Google Scholar :
|
|
36
|
Fukuoka E, Yamashita K, Tanaka T, Sawada
R, Sugita Y, Arimoto A, Fujita M, Takiguchi G, Matsuda T, Oshikiri
T, et al: Neoadjuvant chemotherapy increases PD-L1 expression and
CD8+ tumor-infiltrating lymphocytes in esophageal
squamous cell carcinoma. Anticancer Res. 39:4539–4548. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tran L, Allen CT, Xiao R, Moore E, Davis
R, Park SJ, Spielbauer K, Van Waes C and Schmitt NC: Cisplatin
alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition
in head and neck squamous cell carcinoma. Cancer Immunol Res.
5:1141–1151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y
and Xu D: PD-1/PD-L1 enhanced cisplatin resistance in gastric
cancer through PI3K/AKT mediated P-gp expression. Int
Immunopharmacol. 94:1074432021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu X, Chen L, Liu L and Niu X:
EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and
strategies. Front Oncol. 9:10442019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ashrafizadeh M, Zarrabi A, Hushmandi K,
Kalantari M, Mohammadinejad R, Javaheri T and Sethi G: Association
of the epithelial-mesenchymal transition (EMT) with cisplatin
resistance. Int J Mol Sci. 21:40022020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding
Q, Xu Z and Chen Y: Inhibition of ATM reverses EMT and decreases
metastatic potential of cisplatin-resistant lung cancer cells
through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 38:1492019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Y, Wang D, Peng H, Chen X, Han X, Yu
J, Wang W, Liang L, Liu Z, Zheng Y, et al: Epigenetically
upregulated oncoprotein PLCE1 drives esophageal carcinoma
angiogenesis and proliferation via activating the PI-PLCε-NF-κB
signaling pathway and VEGF-C/Bcl-2 expression. Mol Cancer.
18:12019. View Article : Google Scholar
|
|
43
|
Mao Y, Wang Y, Dong L, Zhang Y, Zhang Y,
Wang C, Zhang Q, Yang S, Cao L, Zhang X, et al: Hypoxic exosomes
facilitate angiogenesis and metastasis in esophageal squamous cell
carcinoma through altering the phenotype and transcriptome of
endothelial cells. J Exp Clin Cancer Res. 38:3892019. View Article : Google Scholar : PubMed/NCBI
|
